A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy.

Saved in:

Bibliographic Details
Title:	A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy.
Authors:	Hsu EJ; Department of Immunology, UT Southwestern Medical Center, Dallas, TX, 75390, USA., Cao X; Department of Pathology, UT Southwestern Medical Center, Dallas, TX, 75390, USA. Xuezhi.Cao@UTSouthwestern.edu., Moon B; Department of Immunology, UT Southwestern Medical Center, Dallas, TX, 75390, USA., Bae J; Department of Pathology, UT Southwestern Medical Center, Dallas, TX, 75390, USA., Sun Z; Department of Pathology, UT Southwestern Medical Center, Dallas, TX, 75390, USA.; Department of Biomedical Engineering, UT Southwestern Medical Center, Dallas, TX, 75390, USA., Liu Z; Department of Pathology, UT Southwestern Medical Center, Dallas, TX, 75390, USA., Fu YX; Department of Immunology, UT Southwestern Medical Center, Dallas, TX, 75390, USA. Yang-Xin.Fu@UTSouthwestern.edu.; Department of Pathology, UT Southwestern Medical Center, Dallas, TX, 75390, USA. Yang-Xin.Fu@UTSouthwestern.edu.
Source:	Nature communications [Nat Commun] 2021 May 13; Vol. 12 (1), pp. 2768. Date of Electronic Publication: 2021 May 13.
Publication Type:	Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
Journal Info:	Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	2041-1723
DOI:	10.1038/s41467-021-22980-w